The Genitourinary Steering Committee (GUSC) was established in 2008. At monthly meetings, the GUSC addresses the design, prioritization, and evaluation of concepts for phase 2 and phase 3 clinical trials in genitourinary cancers. View the GUSC member roster as of November 7, 2025. The committee may periodically hold clinical trials planning meetings (CTPMs) to focus on specific clinical trial related topics.
Task Forces
- Task forces were established to discuss concepts and provide advisory input into concepts in each of the disease subtypes (View the GUSC Task Force member rosters as of November 7, 2025):
- prostate
- bladder
- renal
Committee Highlights
The following are highlights from recent committee and task force activities:
- Combination Therapies for High-Risk Non-Muscle Invasive Bladder Cancer
In December 2022, the Bladder Task Force held a CTPM that focused on defining the next generation of clinical trials with combination therapies to improve bladder preservation rates and survival outcomes for patients with high-risk, including BCG-unresponsive, non-muscle invasive bladder cancer (NMIBC). Read the executive summary and publication in Bladder Cancer on advancing biomarker studies in NMIBC. - Small Renal Masses and Early Stage Renal Cell Carcinoma
In January 2020, the Renal Task Force held a CTPM that focused on improving the management of small renal masses and early-stage cell carcinoma cancer. Read the executive summary. - Novel Therapeutics for Non-Muscle Invasive Bladder Cancer
In March 2015, the Bladder Task Force held a CTPM that focused on how to design clinical trials for non-muscle invasive bladder cancer using immunotherapy agents and targeted agents. Read the executive summary.
Contact
For more information, contact NCI CCCT Program Director, Abdul Tawab Amiri, Ph.D., at atawab@mail.nih.gov.